Business
Biovica Collaborates with Tempus to Expand the Commercial Reach of DiviTum(R) TKa
UPPSALA, SE / ACCESS Newswire / May 13, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, has entered a reference lab agreement with Tempus, a leader in AI and data-driven precision ...
About this update from Biovica International Ab Class B
[{"type":"text","content":"UPPSALA, SE / ACCESS Newswire / May 13, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, has entered a reference lab agreement with Tempus, a leader in AI and data-driven precision medicine. Tempus will offer Biovica's blood-based treatment monitoring test, DiviTum TKa, as part of its comprehensive portfolio of diagnostics for oncologists.","length":417,"tagName":"p"},{"type":"text","content":"Through the collaboration, Biovica and Tempus will work together to commercialize Biovica's FDA-approved DiviTum TKa test, a blood-based test that monitors and predicts treatment response in hormone receptor-positive metastatic breast cancer. Tempus currently works with over 6,500 oncologists in the U.S., providing a collection of precision medicine solutions designed to support physicians in delivering personalized patient care. The collaboration significantly expands Biovica's market reach, leveraging Tempus' established sales network.","length":555,"tagName":"p"},{"type":"text","content":"" We are excited to work with Biovica to bring DiviTum TKa to breast cancer patients. The treatment landscape in estrogen receptor-positive breast cancer has improved dramatically in the last 5 years with the introduction of HER2-targeted agents, a new generation of endocrine inhibitors, and the expansion of CDK4/6i into the adjuvant setting," said Ezra Cohen, MD, Chief Medical Officer, Oncology, at Tempus.","length":420,"tagName":"p"},{"type":"text","content":"" Tempus represents the future of healthcare by enabling data-driven precision medicine using AI. This collaboration significantly enhances our ability to deliver DiviTum TKa to a broader patient population. We are confident that our work together will significantly accelerate uptake for DiviTum TKa in the important community oncologist segment of the US market, " said Anders Rylander, CEO of Biovica.","length":414,"tagName":"p"},{"type":"text","content":"Contact","length":7,"tagName":"p"},{"type":"text","content":"Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: [email protected]","length":80,"tagName":"p"},{"type":"text","content":"Anders Morén, CFOPhone: +46 73 125 92 46E-mail: [email protected]","length":74,"tagName":"p"},{"type":"text","content":"Biovica - Treatment...